版本:
中国

BRIEF-BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks

April 12 BioCryst Pharmaceuticals Inc -

* BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks

* Has received initial regulatory approvals in Europe to initiate zenith-1 exploratory clinical trial this summer

* To explore if single oral doses of liquid formulation of BCX7353 could have utility in treatment of acute angioedema attacks in some patients Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐